Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

New SGLT2 inhibitors claimed by Yamanouchi and Kotoboki

Nov. 5, 2004

Two novel series of PPARdelta agonists developed at Ono

Nov. 5, 2004

New opioid antagonists and their use as antiobesity agents

Nov. 5, 2004

Novel DPP-IV inhibitors identified by Kotobuki researchers

Nov. 5, 2004

Treatment phase begins in pivotal TRIUMPH study of eculizumab for PNH

Nov. 4, 2004

Approvable letter for Nascobal Nasal Spray

Nov. 4, 2004

Two series of MCH receptor antagonists developed at Neurocrine

Nov. 4, 2004

Risedronate found effective in osteoporotic women treated with gastric acid inhibitors

Nov. 4, 2004

New Broad-Novartis Diabetes Initiative for type 2 diabetes

Nov. 3, 2004

Plexxikon and Wyeth team up to develop PPAR modulators

Nov. 3, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Recludix’s first-in-class STAT6 inhibitor shows efficacy in atopic dermatitis
BioWorld Science
Researchers from Recludix Pharma Inc. reported preclinical efficacy data on REX-8756 (SAR-448755), a first-in-class orthosteric STAT6 inhibitor in models of...